Navigation Links
Intrinsic Enrolls First Patient in Barricaid® Trial
Date:2/17/2011

WOBURN, Mass., Feb. 17, 2011 /PRNewswire/ -- Intrinsic Therapeutics, Inc., a developer of novel lumbar spine anulus closure devices, announced today that it has enrolled the first patient, December 17, 2010, in a Randomized Clinical Trial of its Barricaid® device. Barricaid is designed to prevent reherniations following lumbar discectomy, while allowing the surgeon to retain as much of the native nucleus as possible preserving normal disc height and biomechanics. Barricaid accomplishes this by providing the added security of a bone-anchored device that can be used to close larger anular defects or in cases where anular integrity is in question.

The procedure was performed by Guido Dua, M.D., Chief of Neurosurgery, Middelheim Hospital in Antwerp, Belgium. Robert Hes, MD, Principal Investigator at Middelheim, stated, "What I like about the Barricaid device is that it provides an elegant solution to possible reherniation. Barricaid allows for a limited discectomy while offering the potential for secure closure of the anular defect and a reduction in both the risk of recurrent disc herniation and disc height loss.  I was very satisfied with the simplicity and ease of the procedure. I anticipate that we will be able to recreate the outstanding results seen in prior Barricaid studies."

"We are pleased to have begun our randomized study in Europe," said Noel Rolon, Intrinsic Vice President, Regulatory and Clinical Affairs. "The fact that we have started enrolling patients so quickly indicates the level of enthusiasm among our investigators.  It is clear that the positive clinical and commercial results recently presented at the DWG meeting in Bremen and published in the November 2010 issue of the European Spine Journal, provide a strong foundation for this post-marketing study."

Intrinsic is enrolling up to 800 patients in a prospective, randomized, superiority study comparing Barricaid to traditional limited discectomy. "We are exc
'/>"/>

SOURCE Intrinsic Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Intrinsic Bioprobes Announces Issuance of US Patent for Novel Biomarkers and Assays for Myocardial Infarction
2. Micell Technologies Enrolls First Patient in CE Mark DESSOLVE II Study of MiStent™ Drug-Eluting Coronary Stent (DES)
3. Talecris Biotherapeutics Enrolls Patients in Clinical Trial Evaluating Two Doses of PROLASTIN®-C
4. Cardiogenesis Enrolls First Two Patients in Its Feasibility Study of the PHOENIX® Combination Delivery System
5. Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
6. BHR Pharma Enrolls First Patient in Phase 3 SyNAPSe Traumatic Brain Injury Trial
7. Crux Biomedical Enrolls First Patient in Its Retrieve 2 U.S. Pivotal Trial
8. Ophthotech Enrolls Its First Patient in a Randomized, Controlled Phase II Study of E10030 in Macular Degeneration
9. PARI Pharma Enrolls First Patient in Phase 2b Study of L-CsA
10. Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland
11. Facet Solutions Enrolls 100th Patient in US Pivotal IDE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Does your doctor know what ... doctors have recommended marijuana to the over 112,000 currently registered ... the majority of the other roughly 20,300+ active physicians listed ... little about it – even though a poll in February ... say they have tried it. "With marijuana ...
(Date:8/29/2014)... 2014 Diseases largely eradicated in ... returning. Measles was declared eliminated in 2000, yet the ... August 15—the highest incidence in 20 years. In July, ... whooping cough a problem of "epidemic proportions." ... dying from these preventable diseases—in part because some parents ...
(Date:8/29/2014)... UNION CITY, Calif. , Aug. 29, 2014 /PRNewswire/ ... products company manufacturing point-of-care blood instrumentation and consumables to ... Clint Severson , Chairman and Chief Executive Officer, ... Annual Best Ideas Conference 2014 on Tuesday, September 9, ... held at the Omni Berkshire Place Hotel in ...
Breaking Medicine Technology:Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2
... Tenn., April 10 Leading RSV,investigator Dr. John DeVincenzo ... disease that causes bronchiolitis and pneumonia,according to the Centers ... the leading cause of hospitalization of infants in the ... in this age group., DeVincenzo is using the ...
... and drug development and clinical trial, ... BEDMINSTER, N.J., April 9, 2008 Clinsys ... research,organization (CRO), today introduced its Therapeutically-aligned Program,Strategists ... and execution,of clinical trials. The TPS teams ...
Cached Medicine Technology:RSV Researcher Makes Gains in Finding Treatments 2Clinsys(R) TPS Teams Provide Comprehensive Clinical Development Plans 2Clinsys(R) TPS Teams Provide Comprehensive Clinical Development Plans 3
(Date:9/1/2014)... regular family meals may help protect teens from the ... suggests. Online abuse can lead to depression, anxiety ... five adolescents experience cyberbullying," Frank Elgar, a professor at ... University in Montreal, said in a university news release. ... and abuse are difficult for parents and educators to ...
(Date:9/1/2014)... HealthDay Reporter SATURDAY, Aug. ... an experimental drug was more effective than standard treatment ... According to the study authors, the trial was ... new drug, dubbed LCZ696. In the trial, ... (Vasotec), either died or were hospitalized due to heart ...
(Date:9/1/2014)... 2014 Currently, scientists continue to ... for Alzheimer's disease (AD), which reflects their poor ... the diagnosis of the disease, especially in its ... diagnostic tests. In 2014, after decades that ... in the medicine world, there are still no ...
(Date:9/1/2014)... The B-cell non-Hodgkin’s Lymphoma (NHL) treatment market ... (the US, France, Italy, Germany, Spain and the UK), ... 2018. , The competitive landscape in the B-cell NHL ... the UK is poised to undergo a dramatic shift ... largest B-cell NHL indications, which includes Diffuse Large B-Cell ...
(Date:9/1/2014)... 2014 As well as having completed ... currently pursuing counselor certification in Louisiana. , ... CPI training program as well as the Counselor ... both personally and professionally. I am not only ... able to do so. As a Non Violent ...
Breaking Medicine News(10 mins):Health News:Family Meals May Defuse Cyberbullying's Impact, Study Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Narconon Louisiana Announces New Certifications For Staff 2
... Medical Corporation,(CRM:TSX-V) announced today that it has opened a ... Center is the Company,s first in the,state of New ... targeted for,expansion. The opening of this location represents the ... number of Centers to 14., According to the ...
... (IDF) BRIDGES translational research grant program will fund a ... for people at high-risk for getting type 2 diabetes ... develop a healthy lifestyle. , The National Hospital of ... Vietnam. Using diabetes risks questionnaires (1) , the investigators ...
... Gerson Lehrman Group, the world,s,leading marketplace for expertise, ... devoted to providing patients with the,medication information they ... personalized iGuard Risk Ratings, iGuard Safety Alerts,and a ... other registered,users who also want to get informed, ...
... is a chief reason that,patients seek medical attention; ... Physicians must be able to determine which opioid,treatment ... To make clinicians aware of the importance ... Current Clinical Practice and The,Journal of Family Practice: ...
... help breast cancer patients and menopausal women, study finds ... of a local anesthetic into the nerves of the ... long-term relief from hot flashes and sleep deprivation, a ... treatment for breast cancer, especially among women taking anti-estrogen ...
... INC. (Nasdaq:,PDEX) invites shareholders and investors to listen to ... financial results, and a discussion,of the outlook for the ... broadcast live over the Internet on,Thursday, May 15, 2008 ... by,visiting the Company,s website at http://www.pro-dex.com . Mark ...
Cached Medicine News:Health News:CRH Medical Corporation opens Center in New York 2Health News:International Diabetes Federation gives grant to diabetes screening & prevention program in Vietnam 2Health News:Gerson Lehrman Group and iGuard, Inc. Partner to Offer Patients a Voice in Healthcare Industry Decisions 2Health News:Gerson Lehrman Group and iGuard, Inc. Partner to Offer Patients a Voice in Healthcare Industry Decisions 3Health News:Treat Your Patients' Pain Effectively 2Health News:Hot Flashes Reduced by Neck Injection 2Health News:Hot Flashes Reduced by Neck Injection 3Health News:Pro-Dex, Inc. Announces Fiscal 2008 Third Quarter Financial Results Conference Call and Webcast 2
Indications For Usage: ,Used to automatically maintain a low intracuff pressure during long-term intubations....
Indications For Usage: ,Microlaryngeal surgery....
... Indications For Usage: ... ,The monitoring lumen is ... of tracheal gases especially end-tidal ... pressure. , Introducing medication. ...
... onset of VAP. (Valles J, Artigas A, ... subglottic secretions in preventing ventilator-associated pneumonia. Ann ... Auboyer C, Jospe R, et al: Prevention ... role of mechanical subglottic secretions drainage and ...
Medicine Products: